Author:
Gnanendran Subashini Sharon,Turner Lauren Maree,Miller James Austin,Hwang Shelley Ji Eun,Miller Andrew Charles
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference122 articles.
1. Mackiewicz J, Mackiewicz A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Wspolczesna Onkol. 2017;2(1A):68–72.
2. Holmes A, Kern W, Martelli MP, Pucciarini A, et al. Mutations in hairy-cell leukemia. 2011;
3. Czarniecka A, Oczko-Wojciechowska M, Barczyński M. BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg. 2016;5(5):495–505.
4. Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol. 2015;6(6):660–7.
5. Cui G, Liu D, Li W, Fu X, Liang Y, Li Y, et al. A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer. Med (United States). 2017;96(14).
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献